JUXTAPID Drug Patent Profile

Which patents cover Juxtapid, and when can generic versions of Juxtapid launch?

Juxtapid is a drug marketed by Chiesi and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-six patent family members in twenty-one countries.

The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the lomitapide mesylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Juxtapid

Juxtapid was eligible for patent challenges on December 21, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 25, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for JUXTAPID

International Patents:	36
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JUXTAPID

US Patents and Regulatory Information for JUXTAPID

JUXTAPID is protected by two US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on NEW STRENGTH.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-007	Feb 25, 2026		RX	Yes	No	12,472,172
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-006	Apr 23, 2015		DISCN	Yes	No	7,932,268
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-002	Dec 21, 2012		RX	Yes	No	7,932,268
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-001	Dec 21, 2012		RX	Yes	No	7,932,268
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-003	Dec 21, 2012		RX	Yes	No
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-002	Dec 21, 2012		RX	Yes	No	12,472,172

International Patents for JUXTAPID

See the table below for patents covering JUXTAPID around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2005221656	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Canada	2558766	TRAITEMENT A FAIBLES EFFETS SECONDAIRES CONTRE DES AFFECTIONS LIEES A L'HYPERLIPIDEMIE ET L'HYPERCHOLESTEROLEMIE (METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE-EFFECTS)
Canada	2910191	L'UTILISATION D'INHIBITEURS MTP POUR LE TRAITEMENT A FAIBLES EFFETS SECONDAIRES CONTRE DES AFFECTIONS LIEES A L'HYPERLIPIDEMIE ET L'HYPERCHOLESTEROLEMIE (THE USE OF MTP INHIBITORS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS)
Cyprus	1114218
Denmark	1725234
European Patent Office	1725234	TRAITEMENT A FAIBLES EFFETS SECONDAIRES CONTRE DES AFFECTIONS LIEES A L'HYPERLIPIDEMIE ET L'HYPERCHOLESTEROLEMIE (METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE-EFFECTS)

Supplementary Protection Certificates for JUXTAPID

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1725234	132014902228079	Italy		PRODUCT NAME: LOMITAPIDE E OGNI SUA FORMA TERAPEUTICAMENTE EQUIVALENTE COME PROTETTA DAL BREVETTO BASE(LOJUXTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/851/001/-003, 20130805
1725234	SPC/GB14/005	United Kingdom		PRODUCT NAME: LOMITAPIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF OR THE PIPERIDINE N-OXIDE THEREOF; REGISTERED: UK EU/1/13/851/001 20130805; UK EU/1/13/851/002 20130805; UK EU/1/13/851/003 20130805
1725234	300634	Netherlands		PRODUCT NAME: LOMITAPIDE OF HET PIPERIDINE N-OXIDE DAARVAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/851/001-003 20130805
1725234	C 2014 003	Romania		PRODUCT NAME: LOMITAPIDA SAU O SARE ACCEPTABILA FARMACEUTIC SAU PIPERIDIN-N-OXIDUL ACESTEIA; NATIONAL AUTHORISATION NUMBER: EU/1/13/851/001-003; DATE OF NATIONAL AUTHORISATION: 20130731; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/851/001-003; DATE OF FIRST AUTHORISATION IN EEA: 20130731
1725234	2/2014	Austria		PRODUCT NAME: LOMITAPID BZW. DESSEN PHARMAZEUTISCH ANNEHMBARE SALZE; REGISTRATION NO/DATE: EU/1/13/851/001-EU/1/13/851/003 20130731
1725234	CR 2014 00002	Denmark		PRODUCT NAME: LOMITAPID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF ELLER PIPERIDIN N-OXIDET DERAF, HERUNDER LOMITAPIDMESYLAT; REG. NO/DATE: EU/1/13/851/001-003 20130805

Investment Scenario and Fundamentals Analysis for JUXTAPID

Last updated: February 20, 2026

What is JUXTAPID?

JUXTAPID (bempedoic acid) is a lipid-lowering agent developed by Esperion Therapeutics. Approved by the FDA in 2020 to reduce LDL cholesterol in adult patients with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering. It functions as an ATP citrate lyase (ACL) inhibitor, reducing cholesterol synthesis upstream of statins.

Market Position and Commercial Outlook

JUXTAPID faces competition primarily from statins, PCSK9 inhibitors, and ezetimibe. It serves as an oral, potentially lower-cost alternative targeting patients intolerant to statins or needing additional LDL reduction. Its orphan-like niche is defined by specific patient populations with high unmet needs.

Total addressable market (TAM) in the U.S. exceeds 50 million adults with elevated LDL-C, but JUXTAPID's current target market is estimated at a subset of 10 million with intolerance or high residual risk.

Esperion projects peak sales between $700 million and $1 billion, assuming gradual adoption and formulary inclusion. However, market penetration has been slower than initial projections, emphasizing the importance of clinical differentiation, payer acceptance, and provider adoption.

Revenue and Sales Trends

Initial sales since launch in 2020 have been modest, with estimates around $50 million in 2022. Growth depends on expanding indications, approval in additional regions, and increased prescriber awareness.

Patent and Regulatory Landscape

JUXTAPID's patent estate extends into the late 2030s, including composition of matter and formulation patents. However, competition from generics (if they emerge) could pressure pricing.

Regulatory pathways for broader indications or combined therapies are under consideration, with ongoing clinical trials exploring its efficacy as part of combination regimens for hard-to-treat patients.

Clinical and Pharmacological Fundamentals

JUXTAPID's effectiveness depends on its mechanism of action targeting ACL, leading to LDL-C reduction approximately 15-20%. Its safety profile remains favorable but includes concerns about tendon rupture, hyperuricemia, and elevated liver enzymes, warranting monitoring.

It is administered as a daily oral dose, which favors patient compliance versus injectable alternatives.

Financial and Investment Analysis

• R&D Investment: Esperion invested over $200 million from inception through 2022, with ongoing funds allocated toward clinical trials and marketing.
• Profitability: Currently operating at net losses, with gross margins estimated at 70%-80%. Breakeven expected as sales increase.
• Partnerships: Limited licensing deals and distribution agreements restrict major geographic expansion without additional collaborations.

Risks and Challenges

• Market penetration: Slow adoption among clinicians, largely due to competition and lack of familiarity.
• Regulatory hurdles: Pending approvals for expanded uses may face delays or denials.
• Competitive landscape: Dominance of statins and PCSK9 inhibitors reduces market share potential.
• Pricing pressure: Payers may push for discounts or prefer generics, affecting margins.

Investment Thesis Summary

JUXTAPID offers a niche therapy with a clear mechanism, target market, and moderate sales potential. Growth depends on clinical differentiation, regulatory approvals for expanded indications, and successful commercialization strategies. The company's financial health remains vulnerable to market acceptance and competitive pressures.

Key Takeaways

• JUXTAPID is an ACL inhibitor targeting LDL-C reduction, approved for specific hypercholesterolemia cases.
• Its market potential is limited by competition, slow adoption, and pricing pressures.
• Sales are modest but projected to grow gradually, with significant dependence on expanding indications.
• Intellectual property extends into the late 2030s, but generic competition remains a future risk.
• Risk factors include regulatory delays, market acceptance, and payer restrictions.

FAQs

1. What distinguishes JUXTAPID from other lipid-lowering therapies?
It is an oral ACL inhibitor offering a different mechanism of action, suitable for patients intolerant to statins or needing additional LDL-C lowering.

2. How does the market size for JUXTAPID compare to other cholesterol drugs?
Its target market is smaller than statins and PCSK9 inhibitors but fills an unmet need for specific patient groups.

3. What are the main barriers to JUXTAPID's commercial success?
Limited clinician familiarity, competition from established therapies, and payer restrictions.

4. What is the patent outlook for JUXTAPID?
Patents extend into the late 2030s, providing exclusivity, but generic competition could pose risks after patent expiry.

5. Are there ongoing clinical trials for JUXTAPID?
Yes; trials are underway to evaluate additional indications and combination therapies to expand its market applicability.

---

References

1. Esperion Therapeutics. (2021). JUXTAPID (bempedoic acid) prescribing information.
2. U.S. Food and Drug Administration. (2020). FDA approves new drug to treat high cholesterol.
3. MarketWatch. (2022). Bempedoic acid (JUXTAPID): Market analysis and forecast.
4. ClinicalTrials.gov. (2023). Trials involving JUXTAPID for expanded indications.
5. Pharmaprojects. (2022). Patent landscape for ACL inhibitors.